Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05970900 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

Study acronym: PIRKER
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 1, 2023 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Prior to the implementation of preoperative imatinib mesylate therapy, a considerable percentage (ranging from 34.5% to 67.5%) of individuals diagnosed with rectal gastrointestinal stromal tumors (GIST) underwent abdominoperineal resection (APR), a surgical procedure that involved the removal of the anus and necessitated a permanent colostomy. This study aims to investigate the safety and viability of an organ-preserving approach involving preoperative imatinib mesylate treatment in conjunction with local resection for rectal GIST, specifically targeting patients with c-KIT gene mutations.
Trial Details
NCT Number NCT05970900
Lead Sponsor Fujian Medical University Union Hospital
Conditions
(from sponsor)		 Gastrointestinal Stromal Tumor of Rectum
Related terms Gastrointestinal Stromal Tumors, Piebaldism
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov